181 related articles for article (PubMed ID: 35522887)
1. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Zięba N; Gębka-Kępińska B; Sowa P
Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
3. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
4. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
7. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
8. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
9. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
[TBL] [Abstract][Full Text] [Related]
10. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Vališ M; Achiron A; Hartung HP; Mareš J; Tichá V; Štourač P; Halusková S; Angelucci F; Pavelek Z
Drugs R D; 2023 Dec; 23(4):331-338. PubMed ID: 37640862
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
12. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Derfuss T; Bergvall NK; Sfikas N; Tomic DL
Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
[TBL] [Abstract][Full Text] [Related]
15. Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?
O'Higgins L; Gaughan M; McGuigan C; Lally A
Ir J Med Sci; 2022 Aug; 191(4):1683-1685. PubMed ID: 34495479
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
17. REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.
Batista S; Nunes CC; Cerqueira JJ; Martins Silva A; Correia de Sá J; Ferreira J; Mendonça MT; Pinheiro J; Salgado V; Correia AS; Sequeira J; Costa A; Sousa L
Neurol Sci; 2021 May; 42(5):1995-2003. PubMed ID: 32997282
[TBL] [Abstract][Full Text] [Related]
18. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
Benedetti MD; Marangi A; Bozzetti S; Gobbin F; Turatti M; Pea M; Gajofatto A; Mocella S
Mult Scler Relat Disord; 2018 Jul; 23():24-26. PubMed ID: 29734135
[TBL] [Abstract][Full Text] [Related]
19. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
